右美托咪定:进入姑息治疗领域的万能药——叙述性综述与实践推荐
本叙述性综述通过检索1950年至2021年10月21日的PubMed文献(限英、德、法、意语),汇总右美托咪定在姑息治疗及其他学科的实际应用。证据提示其可能减少谵妄发生率和严重程度、减少阿片类药物消耗及术后恶心,并用于酒精、阿片类、海洛因等物质戒断。安全性方面,部分研究报告原有心脏病患者因心动过缓和动脉低/高血压导致严重心血管事件增加;主要经肝代谢,肝功能损害者必须减量。2021年首项前瞻性队列研究报告右美托咪定用于终末期活动性谵妄可降低谵妄强度和躁动,其独特的「清醒镇静」允许患者在镇静下易唤醒并报告舒适或痛苦。
要点
- 右美托咪定可能降低ICU谵妄发生率和严重程度、减少阿片类药物消耗及术后恶心。
- 部分研究报告原有心脏病患者中严重心血管事件增加,与心动过缓和动脉低/高血压相关。
- 主要经肝代谢,肝功能损害患者必须减量。
- 2021年首项前瞻性队列研究报告活动性终末期谵妄中右美托咪定降低谵妄强度和躁动。
- 姑息治疗适应证包括活动性谵妄镇静、癌痛、阿片诱导的高痛敏、肌张力障碍、咳嗽、呕吐、寒战和呼吸困难。
适用人群与场景
- 姑息治疗患者,用于活动性谵妄镇静、癌痛、阿片诱导的高痛敏、肌张力障碍、咳嗽、呕吐、寒战和呼吸困难等症状控制。
- 重症监护环境中用于镇静、减少谵妄、减少阿片类药物消耗及术后恶心,以及酒精、阿片类、海洛因等物质戒断辅助。
- 原有心脏病患者使用需警惕严重心血管事件增加;肝功能损害患者必须减量。
处置流程与药物剂量
- 给药途径主要为静脉(i.v.)和皮下,也可经鼻和颊黏膜给药。
- 与吗啡、氢吗啡酮、东莨菪碱和氟哌啶醇在「注射泵」混合研究中相容。
- 肝功能损害患者必须减量(原文未写明具体减量幅度)。
- 2021年首项前瞻性队列研究报告右美托咪定用于活动性终末期谵妄可降低谵妄强度和躁动,其「清醒镇静」允许患者在镇静下易唤醒并报告舒适或痛苦。
红旗征与不能漏的情况
- 原有心脏病患者中,部分研究报告因心动过缓和动脉低/高血压导致严重心血管事件增加。
研究设计与关键结果
- 本叙述性综述检索PubMed 1950年至2021年10月21日文献,语言限英、德、法、意语,汇总右美托咪定在姑息治疗及其他学科的应用。
- 证据提示右美托咪定可能减少谵妄发生率和严重程度、减少阿片类药物消耗及术后恶心。
- 部分研究报告原有心脏病患者中严重心血管事件增加,与心动过缓和动脉低/高血压相关。
- 2021年首项前瞻性队列研究报告右美托咪定用于活动性终末期谵妄可降低谵妄强度和躁动,作者讨论了其独特的「清醒镇静」特点。
证据类型、等级与局限
- 证据类型:叙述性综述,附带实践推荐。
对床旁实践的改变
- 对活动性终末期谵妄患者,作者报告2021年首项前瞻性队列研究显示右美托咪定可降低谵妄强度和躁动,并讨论其「清醒镇静」允许患者易唤醒并报告舒适或痛苦。
- 原有心脏病患者使用右美托咪定时需警惕严重心血管事件增加,与心动过缓和动脉低/高血压相关。
- 肝功能损害患者必须减量。
- 右美托咪定可与吗啡、氢吗啡酮、东莨菪碱和氟哌啶醇在注射泵中混合使用。
指南或共识出处
- 本叙述性综述发表于Ann Palliat Med,检索PubMed 1950年至2021年10月21日文献。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Dexmedetomidine is a potent adrenergic alpha-2 receptor agonist. It was first approved for sedation for mechanically ventilated patients. Being a sedative medication that is not associated with respiratory depression and holding analgesic properties fosters the interest for this drug in the palliative care field. The primary objectives of this review were to identify the key indications for the real-world use of dexmedetomidine in palliative care and other disciplines.
METHODS: A narrative review after extensive PubMed search was performed from 1950 to present on October 21st 2021. The language of the publications was restricted to English, German, French and Italian.
KEY CONTENT AND FINDINGS: (I) Current dexmedetomidine use. There is a growing body of evidence that dexmedetomidine may reduce the incidence and severity of delirium, reduce opioid-consumption and postoperative nausea in intensive care settings. It is also used to facilitate withdrawal from different substances (alcohol, opioids, heroin). Concerning safety aspects of the drug, some studies reported an increased rate of serious cardiovascular events in patients with pre-existing heart conditions due to bradycardia and arterial hypo- and hypertension. Since the drug has a main hepatic metabolism, dose reduction is mandatory in patients with hepatic impairment. (II) Dexmedetomidine and palliative care. There have been sporadic case reports about the successful use of dexmedetomidine in palliative care. Indications for symptom control included sedation for hyperactive delirium, cancer pain, opioid-induced-hyperalgesia, dystonia, cough, vomiting, shivering and dyspnea. It is mainly applied via the intravenous (i.v.), subcutaneous, but also nasal and, buccal routes. Admixture ("syringe-driver") studies showed that dexmedetomidine is compatible with morphine, hydromorphone, hyoscine and haloperidol. In 2021, a first prospective cohort study became available. Here, the authors reported promising result for dexmedetomidine use in hyperactive terminal delirium for reducing delirium intensity and agitation. Especially the unique "conscious sedation" or "awake sedation" that allows patients to arouse easily under sedation and report comfort or distress was discussed by the authors.
CONCLUSIONS: In this review, we present the main findings for dexmedetomidine from palliative care settings and other disciplines. The potential benefits and criticalities of the drug are discussed and practical recommendations for its use are provided.
参考来源
- Gaertner J, Fusi-Schmidhauser T. Dexmedetomidine: a magic bullet on its way into palliative care-a narrative review and practice recommendations. Ann Palliat Med. 2022. PMID: 35400162. doi:10.21037/apm-21-1989
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。